Mosaic Immunoengineering INC. (CPMV) — SEC Filings

Q: What are the key financial highlights for Mosaic Immunoengineering INC.?

Key financial highlights for Mosaic Immunoengineering INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Mosaic Immunoengineering INC.?

Key executives at Mosaic Immunoengineering INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Mosaic Immunoengineering INC. stock?

Risk factors for Mosaic Immunoengineering INC. (CPMV) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Mosaic Immunoengineering INC.?

Forward-looking statements and predictions from Mosaic Immunoengineering INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Mosaic Immunoengineering INC.. Recent 10-K filing on Apr 15, 2026. AI-decoded analysis of earnings, risk factors, and insider trades

View Mosaic Immunoengineering INC. on SEC EDGAR

Overview

Mosaic Immunoengineering INC. (CPMV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Apr 15, 2026: Mosaic ImmunoEngineering Inc. filed its annual report on Form 10-K for the period ending December 31, 2025. The filing, accepted on April 15, 2026, includes various documents such as the main 10-K report, subsidiary information, and certifications. The company is involved in the biological products

Sentiment Summary

Across 16 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 14 neutral. The dominant filing sentiment for Mosaic Immunoengineering INC. is neutral.

Filing Type Overview

Mosaic Immunoengineering INC. (CPMV) has filed 3 10-K, 6 10-Q, 7 8-K with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (16)

Mosaic ImmunoEngineering Files 2025 Annual Report — 10-K · Apr 15, 2026 Risk: low
Mosaic ImmunoEngineering Inc. filed its annual report on Form 10-K for the period ending December 31, 2025. The filing, accepted on April 15, 2026, includes var
Mosaic ImmunoEngineering's Cash Dwindles Amidst Continued Losses — 10-Q · Nov 19, 2025 Risk: high
Mosaic ImmunoEngineering Inc. (CPMV) reported a net loss of $165,361 for the three months ended September 30, 2025, a 11.4% improvement from the $186,730 net lo
Mosaic ImmunoEngineering Files Q2 2025 10-Q — 10-Q · Aug 19, 2025 Risk: low
Mosaic ImmunoEngineering Inc. filed its quarterly report for the period ending June 30, 2025. The company, previously known as Patriot Scientific Corp and Patri
Mosaic ImmunoEngineering Files Q1 2025 10-Q — 10-Q · May 20, 2025 Risk: low
Mosaic ImmunoEngineering Inc. filed its 10-Q for the period ending March 31, 2025. The company, previously known as Patriot Scientific Corp and Patriot Financia
Mosaic ImmunoEngineering Files 2024 10-K — 10-K · Apr 15, 2025 Risk: low
Mosaic ImmunoEngineering Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Patriot Scientific Corp, is based in H
Mosaic ImmunoEngineering Files 8-K — 8-K · Jan 2, 2025 Risk: low
Mosaic ImmunoEngineering, Inc. filed an 8-K report on January 2, 2025, detailing events as of December 31, 2024. The filing primarily concerns financial stateme
Mosaic ImmunoEngineering Files Q3 2024 10-Q — 10-Q · Nov 19, 2024 Risk: medium
Mosaic ImmunoEngineering Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Patriot Scientific Corp and Patriot Financ
Mosaic ImmunoEngineering Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
Mosaic ImmunoEngineering Inc. filed its quarterly report for the period ending June 30, 2024. The company, formerly known as Patriot Scientific Corp, is involve
Mosaic ImmunoEngineering Adds Biotech Veteran to Board — 8-K · Jul 25, 2024 Risk: medium
Mosaic ImmunoEngineering Inc. announced on July 23, 2024, the election of Dr. Jonathan Lim to its Board of Directors. Dr. Lim brings extensive experience in the
Mosaic ImmunoEngineering Files 8-K: Board & Officer Changes — 8-K · May 31, 2024 Risk: low
Mosaic ImmunoEngineering, Inc. filed an 8-K on May 31, 2024, reporting changes in its board of directors and certain officers, along with updates to compensator
Mosaic ImmunoEngineering Changes Auditors — 8-K · May 21, 2024 Risk: low
Mosaic ImmunoEngineering Inc. announced on May 21, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered pu
Mosaic ImmunoEngineering Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk:
Mosaic ImmunoEngineering Inc. (CPMV) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Mosaic ImmunoEngineering Inc. filed a 10-Q report for the per
BioNTech to Acquire Mosaic ImmunoEngineering — 8-K · Apr 29, 2024 Risk: medium
Mosaic ImmunoEngineering Inc. announced on April 26, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of BioNTech SE. The tr
Mosaic ImmunoEngineering Announces Director Changes — 8-K · Apr 19, 2024 Risk: low
Mosaic ImmunoEngineering Inc. announced on April 17, 2024, the departure of Director Dr. David J. Earp and the appointment of Dr. Robert J. Valeri as a new dire
Mosaic ImmunoEngineering Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 15, 2024 Risk:
Mosaic ImmunoEngineering Inc. (CPMV) filed a Annual Report (10-K) with the SEC on April 15, 2024. Mosaic ImmunoEngineering Inc. filed its 2023 Form 10-K on Apri
Mosaic ImmunoEngineering Enters and Terminates Agreements — 8-K · Mar 28, 2024 Risk: medium
Mosaic ImmunoEngineering Inc. entered into a Material Definitive Agreement on March 22, 2024. The company also terminated a Material Definitive Agreement on the

Risk Profile

Risk Assessment: Of CPMV's 14 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Mosaic Immunoengineering INC.'s most recent 10-Q filing (Nov 19, 2025):

Revenue: $0
Net Income: $-165,361
EPS: $-0.02
Debt-to-Equity: N/A
Cash Position: $31,761
Operating Margin: N/A
Total Assets: $55,298
Total Debt: $7,362,181

Key Executives

Dr. Jonathan Lim
Dr. David J. Earp
Dr. Robert J. Valeri

Industry Context

Mosaic ImmunoEngineering operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often rely on significant research and development investment and face long product development cycles. Success is typically driven by innovation, intellectual property, and the ability to secure substantial funding for clinical trials and commercialization.

Top Tags

biotech (6) · 10-Q (5) · Biotechnology (3) · financials (3) · quarterly-report (2) · biotechnology (2) · 10-K (2) · Mosaic ImmunoEngineering (2) · annual-report (1) · sec-filing (1)

Key Numbers

Documents: 68 — Total number of documents included in the submission.
Bytes: 4354038 — Size of the complete submission text file.
Cash and cash equivalents: $31,761 — Decreased from $115,019 at December 31, 2024, indicating severe liquidity issues.
Net loss (Q3 2025): $165,361 — Represents a continued loss, though an improvement from $186,730 in Q3 2024.
Net loss (YTD Q3 2025): $518,709 — A significant loss for the nine months, albeit lower than $768,939 in the prior year.
Accumulated deficit: $9,357,029 — Increased from $8,838,320 at December 31, 2024, highlighting ongoing losses.
Accrued compensation: $4,135,109 — Increased from $3,767,652 at December 31, 2024, a significant liability.
Convertible notes, net: $1,447,363 — Increased from $1,392,515 at December 31, 2024, adding to debt burden.
Total operating expenses (YTD Q3 2025): $467,986 — Decreased from $729,498 in the prior year, showing cost-cutting efforts.
Common shares outstanding: 7,242,137 — Consistent number of shares, indicating no recent dilution from new equity issuance.
Basic and diluted loss per common share (Q3 2025): $0.02 — Slight improvement from $0.03 in Q3 2024, but still a loss.
Basic and diluted loss per common share (YTD Q3 2025): $0.07 — Improvement from $0.11 in YTD Q3 2024, but still a loss.
Report Period End Date: 20250630 — Indicates the end of the fiscal quarter being reported.
Filing Date: 20250819 — The date the 10-Q was officially submitted to the SEC.
Fiscal Year-to-Date Period: 2025-01-01 to 2025-06-30 — Covers the first six months of the fiscal year 2025.

Related Companies

BNTX

Frequently Asked Questions

What are the latest SEC filings for Mosaic Immunoengineering INC. (CPMV)?

Mosaic Immunoengineering INC. has 16 recent SEC filings from Mar 2024 to Apr 2026, including 7 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CPMV filings?

Across 16 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 14 neutral. The dominant sentiment is neutral.

Where can I find Mosaic Immunoengineering INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Mosaic Immunoengineering INC. (CPMV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Mosaic Immunoengineering INC.?

Key financial highlights from Mosaic Immunoengineering INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CPMV?

The investment thesis for CPMV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Mosaic Immunoengineering INC.?

Key executives identified across Mosaic Immunoengineering INC.'s filings include Dr. Jonathan Lim, Dr. David J. Earp, Dr. Robert J. Valeri.

What are the main risk factors for Mosaic Immunoengineering INC. stock?

Of CPMV's 14 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 8 low-risk.

What are recent predictions and forward guidance from Mosaic Immunoengineering INC.?

Forward guidance and predictions for Mosaic Immunoengineering INC. are extracted from SEC filings as they are enriched.